Undecided

[PL-6] Alectinib in recurrent or refractory ALK-positive ALCL: phase 2 trial in both children and adults

Tetsuya Mori¹, Masahiro Sekimizu^2,3, Reiji Fukano⁴, Ilseung Choi⁵, Kengo Takeuchi⁶, Ukihide Tateishi⁷, Takashi Terauchi⁸, Akiko Kada³, Akiko Saito³, Ryuta Asada⁹, Keizo Horibe^2,3, Hirokazu Nagai^3,10 (1.Pediatrics, St. Marianna University School of Medicine, Kanagawa, Japan, 2.Pediatrics, NHO Nagoya Medical Center, Aichi, Japan, 3.Clinical Research Center, NHO Nagoya Medical Center, Aichi, Japan, 4.Pediatrics, Graduate School of Medicine, Yamaguchi University, Yamaguchi, Japan, 5.Hematology, NHO Kyusyu Cancer Center, Fukuoka, Japan, 6.Pathology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan, 7.Diagnostic Radiology, Tokyo Medical and Dental University, Tokyo, Japan, 8.Nuclear Medicine, Cancer Institute Hospital, Tokyo, Japan, 9.Innovative and Clinical Research Promotion Center, Gifu University, Gifu, Japan, 10.Hematology and Oncology Research, NHO Nagoya Medical Center, Aichi, Japan)